Right to Try

Presented By

Charles Siler

August 3, 2015
Terminal Illness vs. Expanded Access

• Over 1 million Americans die from terminal illness every year, 584,000 died from cancer alone in 2013

• The FDA approves almost all applications for Expanded Access (over 99%), but that number is only about 1,000 per year, or just 0.17% of cancer patients.
Clinical Trials

• Over 97% of interested patients can’t participate in clinical trials.
  – Co-morbidity factors
  – Not sick in the right way
  – Geographic limitations
Access By Public Opinion

Josh Hardy
After beating 3 cancers, he was diagnosed with myelodysplastic disorder a precursor to leukemia. Josh’s family fought to get access to Brincidofovir, an experimental drug by Chimerix.
Risk to Benefit Spectrum

Former FDA Commissioner Alexander Schmidt noted “in all our FDA history, we are unable to find a single instance where a Congressional committee investigated the failure of the FDA to approve a new drug. But the times when hearings have been held to criticize our approval of a new drug have been so frequent that we have not been able to count them.”
Congress & Right to Try

H.R. 3012
Right to Try Act of 2015

Introduced last month

To authorize the use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law, and for other purposes.
2016’s Innovative Healthcare Policy

Right to Shop
A rewards sharing program designed to offer patients more choice while bringing down health care costs.

Community CARES
Encouraging health care providers to offer charity care to our neediest neighbors.
Right to Try Contact Info

Kurt Altman
Senior Attorney
Goldwater Institute
Kaltman@goldwaterinstitute.org
(602) 633-8966
Right to Try

Presented by

Charles Siler

August 3, 2015